Eli Lilly agreed to buy Centessa Pharmaceuticals for $6.3 billion upfront, plus additional potential value via contingent payments, securing Centessa’s orexin receptor 2 (OX2R) agonist pipeline for sleep-wake disorders. The lead program cleminorexton has shown positive Phase 2a results across narcolepsy types 1 and 2 and idiopathic hypersomnia, positioning Lilly for a new competitive front beyond obesity.